Get the Stockscreener App
41.60
1.86%
0.76
After Hours:
41.60
Edgewise Therapeutics Inc stock is traded at $41.60, with a volume of 1.03M.
It is up +1.86% in the last 24 hours and up +0.34% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
See More
Previous Close:
$40.84
Open:
$41.6
24h Volume:
1.03M
Relative Volume:
0.73
Market Cap:
$4.48B
Revenue:
-
Net Income/Loss:
$-176.01M
P/E Ratio:
-25.05
EPS:
-1.661
Net Cash Flow:
$-148.97M
1W Performance:
+7.19%
1M Performance:
+0.34%
6M Performance:
+41.69%
1Y Performance:
+194.62%
1-Day Range:
$40.80
$42.38
1-Week Range:
$37.52
$42.38
52-Week Range:
$12.30
$48.40
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
41.60 | 4.39B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics Inc (EWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Edgewise Therapeutics Inc (EWTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edgewise Therapeutics Inc (EWTX) Balance Sheet - TradingKey
Edgewise Therapeutics Inc (EWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Edgewise Therapeutics, Inc. Revenue Breakdown – NASDAQ:EWTX - TradingView
Edgewise Therapeutics Inc (EWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Edgewise Therapeutics Inc (EWTX) Institutional Confidence - TradingKey
EWTX|Edgewise Therapeutics Inc|Price:40.840|Chg%:+1.550 - TradingKey
TradingKey - TradingKey
Is Edgewise Therapeutics (EWTX) on the Cusp of a Breakthrough Year - Kavout | AI
Edgewise Therapeutics, Inc. (EWTX) options chain - Yahoo Finance Singapore
Edgewise Therapeutics, Inc. (EWTX) stock price, news, quote and history - Yahoo Finance UK
Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified? - Yahoo Finance
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Biotechnology Innovator with a Promising 28.63% Upside - DirectorsTalk Interviews
EWTX Maintained by Evercore ISI Group -- Price Target Raised to $55 - GuruFocus
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $55 - Moomoo
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
(EWTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Form 4 Edgewise Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Edgewise Therapeutics director gets 16,377 options | EWTX Insider Trading - Stock Titan
Edgewise Therapeutics (NASDAQ: EWTX) books big gain on $1.55B sevasemten sale - Stock Titan
Frontier tech research, news & data - MLQ.ai
Servier completes the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business - Macau Business
Boulder biotech unloads muscular dystrophy drug for up to $2.65 billion - The Business Journals
Edgewise closes muscular-dystrophy biz sale in deal that could top $2.6M - BizWest
Edgewise sells sevasemten business for $1.55 billion - grafa.com
Edgewise Therapeutics Sells Sevasemten for Up to $2.65 Billion to Focus on Cardiovascular Drug Pipeline - Minichart
Positive Trial Results Propel Edgewise's (EWTX) Plans for Phase 3 Development - GuruFocus
Servier completes $2.65 billion Edgewise muscular dystrophy buy By Investing.com - Investing.com Nigeria
Edgewise Therapeutics Completes Up to $2.65 Billion Sevasemten Sale to Focus on Cardiovascular Pipeline - citybiz
Edgewise completes sale of sevasemten to Servier for $2.65B By Investing.com - Investing.com Nigeria
Servier completes $2.65 billion Edgewise muscular dystrophy buy - Investing.com
Servier Acquires Muscular Dystrophy Business from Edgewise Therapeutics - Contract Pharma
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
Edgewise (Nasdaq: EWTX) receives $1.55B upfront, pivots to heart drugs - Stock Titan
Edgewise Therapeutics Stock Rides A 5-Day Winning Streak To A 23% Gain - Trefis
Oppenheimer Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $51 - Moomoo
Servier Pharmaceuticals LLC completed the acquisition of Sevasemten and Muscular Dystrophy Business of Edgewise Therapeutics, Inc.. - marketscreener.com
Oppenheimer Initiates Edgewise Therapeutics at Outperform - Moomoo
EWTX Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says - Moomoo
Oppenheimer initiates Edgewise Therapeutics stock with outperform rating By Investing.com - Investing.com India
Oppenheimer initiates Edgewise Therapeutics stock with outperform rating - Investing.com
Price to book forward of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView
Edgewise Therapeutics stock hits all-time high at 43.96 USD - Investing.com UK
Edgewise Therapeutics stock hits all-time high at 43.96 USD By Investing.com - Investing.com South Africa
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):